Binding of the novel nonxanthine A2A adenosine receptor antagonist [3H]SCH58261 to coronary artery membranes. 1996

L Belardinelli, and J C Shryock, and J Ruble, and A Monopoli, and S Dionisotti, and E Ongini, and D M Dennis, and S P Baker
Department of Medicine, College of Medicine, University of Florida, Gainesville 32610-0277, USA.

This study demonstrates quantification of A2A adenosine receptors (A2AAdoRs) in membranes prepared from porcine coronary arteries, porcine striatum, and PC12 cells. Radioligand binding assays were performed using the new selective A2AAdoR antagonist radioligand [3H]-5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo [4,3-epsilon]-1,2,4-triazolo[1,5-c)pyrimidine ([3H]SCH58261). Binding of the radioligand to membranes was rapid, reversible, and saturable. The densities of A2AAdoRs in membranes prepared from porcine coronary arteries, porcine striatum, and PC12 cells were 900 +/- 61, 892 +/- 35, and 959 +/- 76 fmol/mg protein, respectively. Equilibrium dissociation constants (Kd values) calculated from results of saturation binding assays were 2.19, 1.20, and 0.81 nmol/L, and Kd values calculated from results of association and dissociation assays were 2.42, 1.01, and 0.40 nmol/L for [3H]SCH58261 binding to membranes prepared from porcine coronary arteries, porcine striatum, and PC12 cells, respectively. The specific binding of [3H]SCH58261 as a percentage of total binding at a radioligand concentration equal to the Kd value was 65% to 90% in the three membrane preparations. The order of ligand potencies determined by assay of competition binding to sites in porcine coronary membranes using [3H]SCH58261, unlabeled antagonists (SCH58261, 8-(3-chlorostyryl)caffeine [CSC], and xanthine amine congener [XAC]), and unlabeled agonists ([3H]2-p-(2-carboxyethyl)-phenethylamino-5'-N-ethylcarboxamidoaden osine [CGS 21680], 2-hexynyl-5'-N-ethylcarboxamidoadenosine [HE-NECA], [3H]5'-N-ethylcarboxamidoadenosine [NECA], and R(-)N6-(2-phenylisopropyl)adenosine [R-PIA]) was SCH58261 > HE-NECA = CSC = CGS 21680 = XAC > NECA = R-PIA. The Hill coefficients of displacement by A2AAdoR ligands of [3H]SCH58261 binding were not significantly different from unity, indicating that [3H]SCH58261 bound to a group of homogeneous noninteracting sites in all membrane preparations. The order of ligand potencies to compete for [3H]SCH58261 binding sites in porcine striatal and PC12 cell membranes was, in part, different from that for porcine coronary arterial membranes. The different rank orders of potencies for agonists and antagonists at A2A receptors of porcine coronary arteries, striatum, and PC12 cells and significant differences in absolute values of potency of ligands in the three preparations may indicate the existence of different subtypes of A2AAdoRs. The antagonist radio-ligand [3H]SCH58261 should be of value for pharmacological characterization of A2A adenosine receptors in other preparations.

UI MeSH Term Description Entries
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D003331 Coronary Vessels The veins and arteries of the HEART. Coronary Arteries,Sinus Node Artery,Coronary Veins,Arteries, Coronary,Arteries, Sinus Node,Artery, Coronary,Artery, Sinus Node,Coronary Artery,Coronary Vein,Coronary Vessel,Sinus Node Arteries,Vein, Coronary,Veins, Coronary,Vessel, Coronary,Vessels, Coronary
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013552 Swine Any of various animals that constitute the family Suidae and comprise stout-bodied, short-legged omnivorous mammals with thick skin, usually covered with coarse bristles, a rather long mobile snout, and small tail. Included are the genera Babyrousa, Phacochoerus (wart hogs), and Sus, the latter containing the domestic pig (see SUS SCROFA). Phacochoerus,Pigs,Suidae,Warthogs,Wart Hogs,Hog, Wart,Hogs, Wart,Wart Hog
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole
D058915 Purinergic P1 Receptor Antagonists Compounds that bind to and block the stimulation of PURINERGIC P1 RECEPTORS. Adenosine Receptor Antagonist,P1 Purinoceptor Antagonist,Purinergic P1 Receptor Antagonist,Adenosine Receptor Antagonists,P1 Purinoceptor Antagonists,Antagonist, Adenosine Receptor,Antagonist, P1 Purinoceptor,Antagonists, Adenosine Receptor,Antagonists, P1 Purinoceptor,Purinoceptor Antagonist, P1,Purinoceptor Antagonists, P1,Receptor Antagonist, Adenosine,Receptor Antagonists, Adenosine

Related Publications

L Belardinelli, and J C Shryock, and J Ruble, and A Monopoli, and S Dionisotti, and E Ongini, and D M Dennis, and S P Baker
April 1996, British journal of pharmacology,
L Belardinelli, and J C Shryock, and J Ruble, and A Monopoli, and S Dionisotti, and E Ongini, and D M Dennis, and S P Baker
February 2000, Journal of cardiovascular pharmacology,
L Belardinelli, and J C Shryock, and J Ruble, and A Monopoli, and S Dionisotti, and E Ongini, and D M Dennis, and S P Baker
January 1991, Molecular pharmacology,
L Belardinelli, and J C Shryock, and J Ruble, and A Monopoli, and S Dionisotti, and E Ongini, and D M Dennis, and S P Baker
September 1996, The Journal of pharmacology and experimental therapeutics,
L Belardinelli, and J C Shryock, and J Ruble, and A Monopoli, and S Dionisotti, and E Ongini, and D M Dennis, and S P Baker
November 1994, Molecular pharmacology,
L Belardinelli, and J C Shryock, and J Ruble, and A Monopoli, and S Dionisotti, and E Ongini, and D M Dennis, and S P Baker
October 2019, Neurochemistry international,
L Belardinelli, and J C Shryock, and J Ruble, and A Monopoli, and S Dionisotti, and E Ongini, and D M Dennis, and S P Baker
December 2003, Neurology,
L Belardinelli, and J C Shryock, and J Ruble, and A Monopoli, and S Dionisotti, and E Ongini, and D M Dennis, and S P Baker
September 1987, The Journal of pharmacology and experimental therapeutics,
L Belardinelli, and J C Shryock, and J Ruble, and A Monopoli, and S Dionisotti, and E Ongini, and D M Dennis, and S P Baker
November 2020, European review for medical and pharmacological sciences,
L Belardinelli, and J C Shryock, and J Ruble, and A Monopoli, and S Dionisotti, and E Ongini, and D M Dennis, and S P Baker
August 2013, Proteins,
Copied contents to your clipboard!